CLEC12A and leukemia: demonstrated that CLL-1 CAR T cells with additional transgenic IL15 supplementation, and combined with a TNFα blocker antibody as well as activation of caspase-9 control switcher increased expansion, persistence, and anti-leukemia of CLL1 CAR-T cells in PDX and HL60 xenograft mouse models while avoided excessive cytokine production (144).